文章摘要
张焕虎,孙胜波,韩传吉,孙绍伟.双途径化疗对合并门静脉癌栓肝癌患者预后的影响(3年随访报告)[J].中华流行病学杂志,2012,33(11):1181-1184
双途径化疗对合并门静脉癌栓肝癌患者预后的影响(3年随访报告)
A 3-year-follow-up study on the prognosis of ‘two-route chemotherapy’ on liver cancer patients with portal vein tumor thrombus
收稿日期:2012-06-30  出版日期:2014-09-03
DOI:10.3760/cma.j.issn.0254-6450.2012.11.019
中文关键词: 肝细胞肝癌  门静脉癌栓  肝动脉插管化疗栓塞  门静脉化疗
英文关键词: Hepatic cell cancer  Portal vein tumor thrombus  Transcatheter arterial chemoembolization  Portal vein chemotherapy
基金项目:
作者单位E-mail
张焕虎 山东省威海市立医院 264200 ssbwh76@126.Com 
孙胜波 山东省威海市立医院 264200  
韩传吉 山东省威海市立医院 264200  
孙绍伟 山东省威海市立医院 264200  
摘要点击次数: 2685
全文下载次数: 936
中文摘要:
      目的 探讨双途径化疗[经DDS泵门静脉化疗(PVC)联合肝动脉插管化疗栓塞(TACE)]预防术后肝细胞肝癌和门静脉癌栓复发的临床疗效及安全性.方法 将2009年1月至2011年1月威海市立医院收治的87例有手术指征肝癌合并门静脉癌栓患者随机分成3组,切除肿瘤并取癌栓后A组行TACE、B组行经DDS泵PVC,C组行经DDS泵PVC联合TACE.随访3组患者术后6个月及1、2、3年无瘤生存率及累积生存率,并进行统计学分析.结果 术后6个月及1、2、3年无瘤生存率及累积生存率C组均高于A、B组.术后6个月、1年时差异无统计学意义(P>0.05);术后2、3年时差异有统计学意义(P<0.01).上消化道出血的发生率C组与A、B两组间差异无统计学意义(P>0.05).结论 肝细胞肝癌合并门静脉癌栓患者手术切除肿瘤并取癌栓后,行经DDS泵PVC联合TACE较单独PVC或TACE有效提高其远期无瘤生存率及累计生存率,且不增加上消化道出血的发生率.
英文摘要:
      Objective To study the achievements and safety of Transcatheter arterial chemoembolization (TACE) associated Portal Vein Chemo-therapy (PVC) per-drug delivery system (DDS) program in preventing the recurrence of hepatic cell cancer (HCC) and Portal Vein Tumor Thrombus (PVTT). Methods 97 cases with HCC and PVTT were treated from Januay 2009 to January 2011. Patients with tumor or tumor thrombus were resected on all the cases and randomly divided into 3 groups. TACE, PVC per-DDS TACE and PVC per-DDS were given to group A, group B, and group C, respectively. Patients in the 3 groups were followed and compared on the Disease Free Survivals (DFS) and the accumulative survival rates, at 6 months, 1 year and 2 years after the operation. Results After the surgery was completed in June, the 1-year, 2-year, 3-year survival rates and cummulative survival rate in group C was higher than in group A or group. Significant differences did no appeare in June but did show in 1 year after the surgery (P>0.05) as well as in both 2 and 3 years, after the surgery (P<0.01). Conclusion Patients with HCC and PVTT, the TACE chemotherapy in association with PVC per-DDS could increase both the DFSs and accumulative survival rates, when compared to the either single TACE or PVC per-DDS, after the tumor or tumor thrombus were resected.
查看全文   Html全文     查看/发表评论  下载PDF阅读器
关闭